May 24,2024 TOP STORY

Biosensor technology company Allez Health secures $60M

Allez Health, a California-based company formerly known as Zense-Life, has secured $60 million in Series A+ financing, led by Osang Healthcare with participation from existing investors. Allez Health specializes in continuous glucose monitoring (CGM) biosensor technology aimed at enhancing patient performance through comprehensive health data analysis. The company’s leadership team includes former Dexcom executives, with CEO Leif Bowman, CTO Robert Boock, and Chief Science Officer Ted Zhang all having significant experience from Dexcom. The funding will support operations, regulatory filings, manufacturing scaling, and clinical trials.

FUNDING SERIES A

#cgm

View Analyst & Ambassador Comments
Go to original news
May 16,2024

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

Trinity Biotech has partnered with PulseAI to enhance its continuous glucose monitor (CGM) technology with AI-driven health and wellness analytics. Trinity Biotech will provide unique CGM datasets to PulseAI, who will use this data to develop an AI platform for Trinity’s CGM solution. This collaboration aims to create a needle-free, reusable diabetes management solution with superior metabolic insights. Both companies see this partnership as a step towards improved glucose monitoring and broader health analytics.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
May 16,2024

GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

GlucoTrack, Inc. has announced successful results from the first 30 days of a 60-day preclinical study for its implantable continuous glucose monitor, which measures glucose levels in the epidural space. The study showed that the sensor accurately tracked blood glucose levels and a commercially available subcutaneous CGM in animals, with no complications observed. This device aims to simplify disease management for patients with painful diabetic neuropathy. The study will continue to assess the long-term performance of the sensor. If approved, this technology could significantly benefit the millions of people with diabetes affected by neuropathy. The 60-day long-term study is ongoing, with periodic glucose tolerance testing to compare the performance of the Glucotrack epidural sensor performance against blood glucose and subcutaneous CGM.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 09,2024 TOP STORY

Senseonics, Rimidi partner on remote diabetes monitoring program

Senseonics has partnered with Rimidi to develop a remote patient monitoring (RPM) program utilizing Senseonics' Eversense continuous glucose monitor (CGM). The Eversense CGM, known for its long wear time and accuracy, recently received FDA approval for integration with insulin pumps. The RPM program, expected to launch by the third quarter of 2024, aims to optimize diabetes management between office visits. It will integrate Eversense glucose data into Rimidi's clinical management platform, facilitating remote monitoring aligned with Medicare's reimbursable telehealth programs. The collaboration seeks to improve patient engagement, drive workflow optimization, and provide clinical decision support, ultimately enhancing diabetes outcomes and reducing healthcare costs.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
May 10,2024

Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies

This clinical study aimed to characterize glucose levels during uncomplicated pregnancies, defined as pregnancies with normal A1c levels in early pregnancy and without complications like large-for-gestational-age birth or gestational diabetes. A total of 413 pregnant individuals wore Dexcom G6 continuous glucose monitoring (CGM) devices throughout their pregnancy. Results showed stable glucose levels throughout all trimesters, with an overall mean glucose level of 98 mg/dL. Most time was spent within the target range of 63-120 mg/dL, with rare instances of levels above 140 mg/dL. Post-prandial peak glucose was 126 mg/dL on average. Higher mean glucose levels were associated with higher body mass index (BMI). These findings provide insight into glucose levels during uncomplicated pregnancies and can inform treatment targets for pregnant individuals.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 02,2024

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

Glucotrack, Inc., a medical device company focusing on innovations for diabetes, has had two abstracts accepted for poster presentation at the American Diabetes Association's Scientific Sessions in June 2024. The posters will discuss preclinical animal studies and sensor longevity simulation modeling for their Continuous Blood Glucose Monitor (CBGM). Presentation details and poster content will be available on Glucotrack's website after the conference.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 30,2024

Eversense® CGM System Receives iCGM Designation by the US FDA

Senseonics Holdings and Ascensia Diabetes Care announced that the Eversense continuous glucose monitoring (CGM) system has received integrated CGM (iCGM) designation from the US FDA. This marks the first fully implantable device in this category, authorized for marketing through the FDA's De Novo pathway. The iCGM status allows Eversense to integrate with compatible medical devices, such as insulin pumps, particularly for automated insulin delivery (AID) systems. The companies intend to pursue partnerships with various pump manufacturers to offer users of diabetes devices a new interoperable CGM option suitable for AID systems.

REGULATORY FDA

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 15,2024

DexCom, MD Revolution Unite to Boost Diabetes Management

DexCom and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.  As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed decisions and provide better patient care. MD Revolution offers a remote care management platform that seamlessly integrates with an ecosystem of EHRs, data partners, and devices to power comprehensive remote care for large practices, health systems and healthcare organizations. 

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 22,2024

Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial

This RCT research aimed to compare the effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) over 12 months in adults with insulin-treated type 2 diabetes. The study, conducted at Steno Diabetes Center Copenhagen, Denmark, involved 76 participants with poorly controlled type 2 diabetes. Results showed that CGM use led to significantly greater improvements compared to BGM in several key areas. These included an increase in time spent in the target glucose range, a decrease in HbA1c levels, a reduction in total daily insulin dose, weight loss, and improvements in self-rated diabetes-related health, well-being, satisfaction, and health behavior.

CLINICAL STUDY

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 10,2024

Newfoundland and Labrador expands access to continuous glucose monitoring program

Newfoundland & Labrador (Canada)'s Government expands its continuous glucose monitoring program in Budget 2024, now including patients up to age 25 with type 1 diabetes (T1D) enrolled in the NL Insulin Pump Program and pregnant individuals with gestational diabetes. Previously limited to those under 18, a one-year pilot project paved the way for this expansion. With an investment of nearly $1.8 million, the program becomes permanent, benefiting from JDRF Canada's support.

PRODUCT

#reimbursement

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM